Work With Us

Science & Platform

  • Home
  • /
  • Science & Platform

TriCAR-T Platform

TriCAR-T for deeper and more durable responses in B-cell cancers.

Immuna’s lead program is a TriCAR-T cell therapy targeting CD19, CD20, and CD22, designed to:

  • Reduce relapse driven by loss of a single antigen
  • Address tumour heterogeneity in B-cell leukemias and lymphomas
  • Fit into short, robust manufacturing processes suitable for decentralized GMP sites

Key scientific features:

  • Modern CAR architecture with optimized co-stimulatory domains
  • Closed-system, low-touch manufacturing
  • Harmonised release criteria (potency, viability, sterility, vector copy number)
  • Digital batch records and cross-site quality monitoring

Decentralized GMP & Operations

High-quality manufacturing, where care is delivered.

Immuna enables hospitals and regions to operate Immuna-enabled GMP suites integrated into their existing infrastructure.

Each site benefits from:

  • Standardised SOPs and quality manuals
  • Curated equipment for short (1–7 day) manufacturing cycles
  • Training for technicians, pharmacists, and clinicians
  • Remote monitoring, digital batch review, and deviation management
  • Integrated logistics and near-patient product return
  • Regional hubs support multiple spoke hospitals, ensuring quality, redundancy, and scale.

Pipeline

Cell therapies for HIV

  • Stem-cell gene therapies for sickle cell disease and β-thalassemia
  • Multiple myeloma and AML CAR-T programs
  • Selected solid tumour indications in collaboration with academic partners